ArticleWorld journal of urology2009
[(11)C]choline PET/CT in prostate cancer patients with biochemical recurrence after radical prostatectomy.
Article in World journal of urology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data.European journal of nuclear medicine and molecular imaging · 2016Pooled it
- Detection of recurrent prostate cancer with 18F-fluorocholine PET/CT in relation to PSA level at the time of imaging.Annals of nuclear medicine · 2012Trial
- [18F]fluoroethylcholine-PET/CT imaging for radiation treatment planning of recurrent and primary prostate cancer with dose escalation to PET/CT-positive lymph nodes.Radiation oncology (London, England) · 2011Trial
- Target identification for the diagnosis and intervention of vulnerable atherosclerotic plaques beyondEuropean journal of nuclear medicine and molecular imaging · 2019Article
- Article
- Role of PET imaging for biochemical recurrence following primary treatment for prostate cancer.Translational andrology and urology · 2018Review
- Trigger pSA predicting recurrence from positive choline PET/CT with prostate cancer after initial treatment.Oncotarget · 2018Article
- Lymph node imaging in initial staging of prostate cancer: An overview and update.World journal of radiology · 2017Review
- Radiotherapy response evaluation using FDG PET-CT-established and emerging applications.The British journal of radiology · 2017Review
- Clinical Translation and First In-Human Use of [Theranostics · 2017Article
- 68Ga-PSMA PET/CT imaging in recurrent prostate cancer: Where are we now?Central European journal of urology · 2017Review
- PET/CT with (18)F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?European journal of nuclear medicine and molecular imaging · 2016Article
- 68Ga-PSMA-PET/CT in Patients With Biochemical Prostate Cancer Recurrence and Negative 18F-Choline-PET/CT.Clinical nuclear medicine · 2016Article
- Comparison of meta-analyses among elastosonography (ES) and positron emission tomography/computed tomography (PET/CT) imaging techniques in the application of prostate cancer diagnosis.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Article
- [Salvage lymphadenectomy in patients with prostate cancer recurrence: A review].Der Urologe. Ausg. A · 2016Review
- Radiation Therapy after Radical Prostatectomy: Implications for Clinicians.Frontiers in oncology · 2016Review
- A paradigm shift from anatomic to functional and molecular imaging in the detection of recurrent prostate cancer.Future oncology (London, England) · 2014Review
- Advanced imaging for the early diagnosis of local recurrence prostate cancer after radical prostatectomy.BioMed research international · 2014Review
- Preclinical evaluation of BAY 1075553, a novel (18)F-labelled inhibitor of prostate-specific membrane antigen for PET imaging of prostate cancer.European journal of nuclear medicine and molecular imaging · 2014Article
- Functional and molecular imaging: applications for diagnosis and staging of localised prostate cancer.Clinical oncology (Royal College of Radiologists (Great Britain)) · 2013Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate [(11)C]choline positron emission tomography/computed tomography ([(11)C]choline PET/CT) for the detection of a biochemical recurrence of prostate cancer after radical prostatectomy.
methodsRetrospective analysis of [(11)C]choline PET/CT performed in 41 consecutive prostate cancer patients with a rising PSA. The mean time to biochemical relapse was 24 months. PSA levels were determined at time of examination, and patients received either a targeted biopsy or surgery. Histopathology reports served as reference for the evaluation of the [(11)C]choline PET/CT findings.
resultsMean PSA in [(11)C]choline PET/CT positive patients was 3.1 ng/ml (median 2.2 ng/ml, range 0.5-11.6 ng/ml) and 0.86 ng/ml in [(11)C]choline PET/CT negative patients (median 0.83 ng/ml, range 0.41-1.40 ng/ml). Six of 12 patients with PSA < 1.5 ng/ml [(11)C]choline PET/CT revealed a pathological uptake. Histopathology was positive in 6/12 patients in this group. At PSA levels ranging from 1.5 to 2.5 ng/ml all [(11)C]choline PET/CT were positive (n = 16), a positive histology was found in 12/16 patients (75%) and at PSA 2.5-5 ng/ml [(11)C]choline PET/CT was positive in 8/8 patients, confirmed by histology in 7/8 patients. Finally, at PSA higher than 5 ng/ml [(11)C]choline PET/CT identified 5/5 patients positive all confirmed by histology. The sensitivity of [(11)C]choline PET/CT for the detection of recurrence at PSA < 2.5 ng/ml was 89% with a positive predictive value of 72%.
conclusion[(11)C]choline PET/CT is useful for re-staging of prostate cancer in patients with rising PSA even at levels below 1.5 ng/ml. Our study confirms results from other published studies on [(11)C]choline PET/CT in prostate cancer relapse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.